Drug Profile
Research programme: anti-cancer polymeric micelle therapeutics - Samyang Biopharmaceuticals Corporation
Alternative Names: B 6036; B 6061Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Sep 2023 Preclinical trials in Cancer in South Korea (Parenteral) (Samyang Biopharmaceuticals Corporation pipeline, August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 03 Mar 2016 Preclinical trials in Cancer in South Korea (Parenteral) before March 2016